Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
about
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancerPrognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancerIncreased expression of tumor proliferation genes in Hispanic women with early-stage breast cancerIs breast cancer staging obsolete?Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.Ki-67 is a prognostic marker for hormone receptor positive tumors.Dynamics of Protein Expression Reveals Primary Targets and Secondary Messengers of Estrogen Receptor Alpha Signaling in MCF-7 Breast Cancer CellsBreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcomeKi67 and proliferation in breast cancer.Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?The Relationship of Race, Oncotype DX, and Ki67 in a Population Highly Screened For Breast Cancer.The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).When should genetic testing be performed in patients with neuroendocrine tumours?Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.Spotlight on the utility of the Oncotype DX® breast cancer assay.Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
P2860
Q21089802-FE121AFE-378C-42C9-AE9A-098AC2E74DB5Q27853207-6184E6AD-F39C-4C4B-B72B-00D80A2780B9Q31152670-207EF0DC-AF9F-45CD-8CB0-45EBD3BAA080Q35596953-890BEC59-9839-4000-91F1-0809D2758969Q36136837-FEB82D9F-E640-4DE6-A952-BA45FECAD1E4Q36824352-E02B1CAF-35D0-4001-B72C-96A92FFB64ABQ37245861-60BD5537-E127-4335-9746-2D3FB3FD43ECQ37372273-3EDFD322-CF27-43D7-95BD-0E248A89A414Q37689788-6DBFAD74-6809-4EE3-8509-7B3ADC2679FAQ38084286-948755C7-5FDF-45E2-8BD7-ED8A7133284DQ42344024-1A4BC58A-82A5-488C-9A7E-40018091547AQ46162590-39C5BD25-1922-4956-890B-19E56620DD42Q47205521-BAB6CFA3-5786-4C9F-A4EB-45E4CCC63C91Q47869675-BD815271-7FBD-4578-B9B1-39829828F01EQ47921456-8607E667-86BB-42BD-96D2-6D92A9256E87Q48270057-4B1BA77D-C585-4765-9513-E24BD0DF5653Q50921836-7411EF58-4A95-4067-BE93-13F66A18B09BQ52728983-C8BFEEA4-B54F-4BDF-BC8F-44F51B48EA54Q52936770-E43B6233-14E7-4C49-AFA1-887FEE722D21
P2860
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
@ast
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
@en
type
label
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
@ast
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
@en
prefLabel
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
@ast
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
@en
P2093
P2860
P356
P1476
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
@en
P2093
C Ferrario
D Pilavdzic
L C Panasci
M-L Brisson
N Bouganim
S Sahebjam
W H Miller
P2860
P2888
P304
P356
10.1038/BJC.2011.402
P407
P577
2011-10-04T00:00:00Z